Plus Therapeutics (PSTV) Soars 40% as Firm Seals Partnership with United Healthcare

We recently published Massive Gains: 10 Stocks Investors Can’t Stop Buying. Plus Therapeutics Inc. (NASDAQ:PSTV) is one of the top performers on Thursday.

Shares of Plus Therapeutics soared by 39.29 percent on Thursday to finish at $0.5630 apiece as investors cheered a national coverage agreement with UnitedHealth Group Inc.

Under the partnership, Plus Therapeutics Inc. (NASDAQ:PSTV), through its subsidiary CNSide Diagnostics LLC, will provide CNSide Cerebrospinal Fluid Tumor Cell Enumeration laboratory developed test (LDT) to over 51 million people in the US.

Dianthus Therapeutics (DNTH) Hits New High as Drug Trial Sparks Optimism for Blockbuster Potential

Romaset/Shutterstock.com

The deal could translate into higher revenues for CNSide and Plus Therapeutics Inc. (NASDAQ:PSTV).

The CNSide CSF Assay Platform supports rapid diagnoses, treatment monitoring, and treatment guidance for patients with leptomeningeal metastases.

According to Plus Therapeutics Inc. (NASDAQ:PSTV), more than 11,000 CNSide tests have been performed at more than 120,000 cancer institutions since 2020, delivering high sensitivity and specificity of 92 percent and 95 percent, respectively, while influencing treatment decisions in 90 percent of cases.

While we acknowledge the risk and potential of PSTV as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than PSTV and that has 10,000% upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.